With 1.72 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.9 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $13.79 whereas the lowest price it dropped to was $13.0901. The 52-week range on LQDA shows that it touched its highest point at $19.41 and its lowest point at $8.26 during that stretch. It currently has a 1-year price target of $30.80. Beta for the stock currently stands at 0.04.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LQDA was down-trending over the past week, with a drop of -2.20%, but this was down by -11.44% over a month. Three-month performance dropped to -12.01% while six-month performance rose 28.91%. The stock gained 17.18% in the past year, while it has gained 12.21% so far this year. A look at the trailing 12-month EPS for LQDA yields -1.56 with Next year EPS estimates of -0.11. For the next quarter, that number is -0.42. This implies an EPS growth rate of 7.31% for this year and 93.17% for next year.
Float and Shares Shorts:
At present, 85.30 million LQDA shares are outstanding with a float of 69.01 million shares on hand for trading. On 2025-05-30, short shares totaled 16.59 million, which was 1940.9998999999998 higher than short shares on 1745971200. In addition to Dr. Roger A. Jeffs Ph.D. as the firm’s CEO & Director, Mr. Michael Kaseta serves as its COO & CFO.
Institutional Ownership:
Through their ownership of 0.65042996 of LQDA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, LQDA reported revenue of $3120000.0 and operating income of -$35425000.0. The EBITDA in the recently reported quarter was -$33246000.0 and diluted EPS was -$0.45.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LQDA since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With LQDA analysts setting a high price target of 45.0 and a low target of 6.0, the average target price over the next 12 months is 30.8. Based on these targets, LQDA could surge 226.56% to reach the target high and fall by -56.46% to reach the target low. Reaching the average price target will result in a growth of 123.51% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.4234 being high and -$1.659 being low. For LQDA, this leads to a yearly average estimate of -$1.5412.
